HF
TYRA icon

HRT Financial’s Tyra Biosciences TYRA Stock Holding History

HRT Financial’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-17,999
Closed -$253K – 3885
2021
Q4 		$253K Sell
17,999
-13,806
-43% -$274K ﹤0.01% 2377
2021
Q3 		$559K Buy
+31,805
New +$608K ﹤0.01% 1877

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

HRT Financial's TYRA Position: Q1 2022 in Review

HRT Financial sold out of Tyra Biosciences (TYRA) in Q1 2022, closing a stake of 17,999 shares — an estimated $253K sold.

HRT Financial first reported a position in TYRA in Q3 2021 and held it in 2 quarters. The position peaked at $559K in Q3 2021. 46 funds tracked by Wall St. Rank hold TYRA as of Q1 2022.

  • HRT Financial reported no remaining Tyra Biosciences position as of Q1 2022 after selling out during the quarter.
  • HRT Financial sold 17,999 Tyra Biosciences shares in Q1 2022, an estimated $253K.
  • HRT Financial first reported a position in Tyra Biosciences in Q3 2021 and held it in 2 quarters.
  • HRT Financial's Tyra Biosciences position peaked at $559K in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2022.

Based on HRT Financial's 13F filing for Q1 2022, filed 16 May 2022.